

Biotech Outlook 2020

Luncheon/Webcast of June 2, 2011 at Aureole Restaurant in New York

Abstract

This presentation will address the future of the still-emerging biotech industry, including:

- What will the next wave of biotech innovation come from, and what will it look like?
- What are the investment opportunities and how will they be funded?
- What are the incentives likely to shape the biotech industry going forward?
- Will the dilemma "To be or not to be a biotechnology company" persist?

The healthcare sector is in the midst of some extraordinary changes, and as a result, biotech that supplies new and innovative products into this marketplace is facing huge challenges. Some of the market forces that are re-shaping biotech include:

- Impending changes in the U.S. healthcare system
- Escalating operating and research costs
- Inability of big pharma to innovate faster than its blockbusters become generic
- Biotech companies being acquired at a record pace

Join us to meet and talk with Needham and Company's head of equity research in this exciting and fast-changing Biotechnology sector.

Speaker

Mark Monane, M.D., M.S., Managing Director, Equity Research, Biotechnology & Life Sciences, Needham & Company, LLC

Biography



Dr. Mark Monane joined Needham & Company in 2000. He currently serves as Needham's Senior Analyst in biotechnology and biopharmaceuticals covering small and mid-cap stocks in the therapeutics areas of cardiovascular medicine, oncology, CNS/metabolic diseases, and infectious/inflammatory disorders. Dr. Mark's research on medication use and geriatrics has resulted in more than 50 original articles and review publications in journals such as Archives of Internal Medicine, Journal of the American Medical Association, Journal of the American Geriatrics Society, Hypertension and Clinical Pharmacology and Therapeutics. He served as an Assistant Professor of Medicine at Harvard Medical School until he joined Merck-Medco Managed Care as Senior Director of Geriatrics in 1996. He is also an Adjunct Associate Clinical Professor at Rutgers School of Pharmacy in New Jersey. Mark is board certified in internal medicine, geriatric medicine, clinical pharmacology, utilization review/quality assurance, and healthcare management. He holds an AB degree from Columbia University, an MD from New York University School of Medicine, an MS degree from Harvard School of Public Health, and an MBA from Columbia Business School. He completed postdoctoral training in primary care internal medicine at Montefiore Hospital, geriatric medicine at Harvard Medical School, and geriatric clinical pharmacology at Harvard Medical School.

Register now using the link: www.cmeacs.org

Chemical Marketing & Economics Group
A sub-section of the American Chemical Society's New York Section, Inc.
www.cmeacs.org • cmeglobal@gmail.com • T: (212) 488-1798



Sponsors

**Paul
Pospisil**

CM&E Director



Licensing Executives Society
(U.S.A. and Canada), Inc.

Schedule

Location:

Aureole Restaurant
135W 42nd Street, NYC
(between 6 & 7 Av)

Event Times: (EDT)

11:15 am - 12:00 noon
Registration and
Networking
12:00 noon - 1:00 pm
Luncheon
1:00 pm - 2:00 pm
Presentation & Webcast

Luncheon Fees:

\$70 for 2011 members
of CM&E, BACC, NYSCC,
or CPPA
\$90 for Non-Members
Early-bird rates discount
Webcast : \$30 for all.
\$15 discount if reserved
by Friday prior to event.

About CM&E

The Chemical Marketing & Economics Group organizes monthly luncheons and webcasts where industry leaders present original research and cutting-edge outlooks on business, economy, and technology in energy, materials & life science.